

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

In re Application of: Olsen, et al.

For: ACTIVE AIR REMOVAL FROM EXTRACORPOREAL BLOOD CIRCUIT

Serial No.: 10/743,599

Filed: 12-22-2003



CERTIFICATE UNDER 37 CFR §1.8 I hereby certify that this **Information Disclosure Statement Transmittal** and the paper(s), as described herein are being deposited with the United States Postal Service, with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 13th day of February, 2007

Signature

Jo L. Brecht

Printed Name

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

We are transmitting herewith the attached:

- ☒ Information Disclosure Statement Transmittal
- ☒ Supplemental Information Disclosure Statement
- ☒ PTO FORM 1449
- ☒ Copies of cited Other Documents
- ☒ Return Postcard

☒ Please charge Deposit Account No. 13-2546 \$180.00 for the Supplemental Information Disclosure Statement.

☒ Please charge any additional fees or credits to Deposit Account No. 13-2546 which may have been overlooked on this Information Disclosure Statement Transmittal with regard to this filing. A duplicate of this transmittal is enclosed.

Date

February 13, 2007

Jeffrey J. Hohenshell, Reg. No. 34,109
Telephone: (763) 391-9661
Customer No.: 27581



PATENT
Docket: P-11209.06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):	Robert W. Olsen, et al)	Art Unit: 3761
)	
Serial No.:	10/743,599)	Examiner: Leslie R. Deak
)	
Filed:	12-22-2003)	
For:	ACTIVE AIR REMOVAL FROM EXTRACORPOREAL BLOOD CIRCUIT		

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application.

Consideration of each of the documents listed on the attached Form 1449 is respectfully requested. Pursuant to the provisions of M.P.E.P. §609, Applicant further requests that a copy of the Form 1449, marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

The filing of this supplemental information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

The Examiner's attention is directed to the enclosed documents labeled CV 038666 – CV 038724. Upon information and belief, these documents were publicly presented at the NewEra Cardiac Care: Innovation & Technology symposium, held in January, 2002, in Dana Point, California. A list of several presenters, including the attached presentation of James Beck is also enclosed. The audio file for this presentation may be found at:


<http://static.cjp.com/gems/test/NE2002.3.Beck.mp3>.

Should the Examiner require anything further, the Examiner is invited to telephone the undersigned directly at 763-391-9661.

Please charge the fee of \$180.00 pursuant to 37 C.F.R. Section 1.17(p) for the submission of this supplemental information disclosure statement to Deposit Account No. 13-2546.

Respectfully submitted,

Robert W. Olsen, et al
By their Representatives,

By: 
Jeffrey J. Hohenshell
Attorney for Applicant
Registration No. 34,109
Telephone: (763) 391-9661
Customer No.: 27581

Group: 3761[illegible][illegible]

			Documents labeled CV 038666 – CV 038724 produced in CardioVenton, Inc. v. Medtronic, Inc., U.S. District Court, District of Minnesota, Civil File No. 04-CV-02669 (59 pages).
			Agenda for New Era 2002 Perfusion Mini-Symposium held in January 2002 (1 page).

Date Considered

Patent and Trademark Office, U.S. Department of Commerce